trading halt, page-54

23 September 2013

"In 2012, the Company announced it had executed an exclusive Joint Development Agreement (JDA) with P&G, the world’s largest consumer products company. During the 2013 financial year, this collaboration led to the development of a number of custom magnetic micro-arrays designed to enhance the time to onset and level of performance of several key P&G ingredients used across multiple consumer products. Early successes in evaluation programs encouraged a rapid move to the design and development of consumer relevant prototypes for clinical trialing. These study programs are progressing and are expected to conclude by the end of 2013."


28 November 2013

"Clearly P&G are foremost on every one’s mind. P&G are the world’s largest consumer company, you virtually cannot open your kitchen cupboard or your bathroom cupboard without being inundated with P&G products they have over 2000 of the world’s biggest selling sku’s. Our relationship with P&G is in an exclusive area within their Beauty & Grooming group and that is divided into 7 sub categories and we’re working with those - skincare clearly being the foremost one that we’re moving forward with. We have completed the first of 3 clinical studies and in fact the most important of those with P&G. Before you ask, no I can’t tell you what the outcomes of those are because the clinical results are not OBJ’s property, however the outcomes are being sufficiently engaging for them that we have now moved forward into negotiations regarding product development for the first application of OBJ’s technologies across P&G’s product range. I hope to be able to expand on that in coming announcements shortly."

28 February 2014

"The highlight of the period was the completion of the first human clinical efficacy study conducted in China. The 80 person study sought to evaluate the efficacy of OBJ’s non-powered Wand technology on a range of industry standard cosmetic indices using high resolution imagery, expert dermatology evaluations and consumer perception data. Negotiations are underway for the Company’s first Product Development and an expansion of the work programs into a number of new categories."

02 May 2013

"OBJ announced that it had manufactured and shipped the first clinical trial eSkin™ units to its partner’s Contract Research Organization in the US. The shipment was part of the Exclusive Collaboration Agreement involving the Company’s proprietary eSkin™ technology, announced to the market on 25th February 2013. The clinical trial units were developed by the Company in consultation with its partner’s scientific teams in the USA and Europe and will be evaluated in an independent clinical efficacy study in the USA.

The clinical trial will serve to prove up efficacy in humans for marketing claims and, subject to success in the clinical trial, as a pre-cursor to potential licensing, supply and global distribution. eSkin™ incorporates OBJ’s patented Dermaportation powered transdermal delivery technology that has been shown to enhance the delivery of key anti-aging and skincare ingredients deeper and more effectively into the skin. The clinical trial is designed to demonstrate consumer perceivable levels of performance improvement including more rapid reduction of fine lines and wrinkles in comparison with the commercial formulation applied by hand. The use of an independent CRO validates the data generated to then be potentially used commercially throughout the world. If successful the clinical trial will be a major step forward for the Company in the commercial development of its powered drug delivery technology and web-enabled personalization capabilities that allow eSkin™ to optimize cosmetic delivery precisely to individual needs via the world wide web using portable devices."

28 November 2013

"The Coty – philosophy clinical program was a very large one in the U.S and is now complete. Again, the results are not ours, I can’t share it with you, however I think that you can clearly see that the results have been sufficiently engaging and encouraging that we are now have moved forward and philosophy and OBJ are currently in negotiations for a development program which will lead on to a licensing agreement, from there - relatively advanced on those sections, so those 2 major clinical events that we announced earlier in the year have achieved everything that OBJ wished to and have been sufficiently encouraging that we are now engaged with these major parties on how you now turn those into products."

28 February 2014

"The highlight of the Coty collaborations was the completion of the large human clinical efficacy study conducted in the USA during the reporting period. This clinical study sought to evaluate the effect of OBJ’s powered Dermaportation technology on key cosmetic anti-ageing outcomes using both expert assessment and consumer perceptions. The outcomes of this study resulted in negotiations for a Product Development and those discussions have commenced."

Would be interesting if the company came out and surprised us all with the trifecta ;)

23 September 2013

"While the Company has a number of international partnering programs in various stages, the relationships with Procter & Gamble (P&G), GlaxoSmithKline (GSK) and Coty are particularly important initiatives."